Q2 FY27 — 23 Oct 2026
Torrent Pharmaceuticals Limited Q2 FY27
Torrent Pharma delivered strong Q2 FY27 results with consolidated revenue advancing 51% YoY to ₹4,979 crores and EBITDA rising 54% YoY to ₹1,666 crores, aided by the merger of JB effective July 8, 2026. The base India branded business outperformed industry growth at 20% YoY, supported by new launches and Curatio's 34% growth. While transient integration disruptions impacted JB's international business and Germany faced structural pricing headwinds, management expects overall JB growth to rebound to double digits in H2 FY27 and cost synergies to materialize ahead of the original three-year sche
Read the full call






